The purpose of this study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major cardiovascular events when initiated as soon as possible in adult patients who have had a heart attack. Ziltivekimab is a medication designed to reduce inflammation after a heart attack, and thereby reduce secondary cardiac events.
The purpose of the study is to determine whether a 26-week exercise training program or cognitive training program can improve sleep quality in stroke survivors who are experiencing poor sleep quality.
The purpose of this study is to assess the effects of blood thinners in patients who develop short-term atrial fibrillation during surgery, and to determine whether blood thinners can lower the risk of stroke in this population.
The purpose of this study is to identify gaps in health services and make recommendations for the development of high-quality and equitable systems of stroke care informed by young women stroke survivors' experiences.
The purpose of this study is to test the comparative effectiveness of two types of cardiac resynchronization therapy (CRT) lead implantations (His vs LBBP) in relation to patient-centered outcomes (e.g. quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications and re-interventions (e.g. lead dislodgement, infection) relative to standard of care biventricular pacing.
The purpose of the study is to find the best technique and tools for gaining access to left and right heart arteries using x-rays that show blood flow, in patients who are having a specific Medtronic heart valve inserted.
The purpose of the study is to evaluate the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure.
The purpose of the study is to compare differences in blood flow and valve pressures by two different methods in patients who are having transcatheter aortic valve replacement.
Familial hypercholesterolemia (FH) is the most frequent genetic lipoprotein disorder associated with premature coronary artery disease. The goal of this initiative is to create a registry of subjects with FH across Canada. The registry will help clinicians and researchers to determine the burden of disease and the long-term effects of treatment.
Research study which tests the safety and effectiveness of a new vascular closure device to close the femoral access puncture that is created in patients who require this form of access in order to perform the planned procedure. The MANTA device is expected to seal the femoral access puncture in less than 1 minute. This may result in less blood loss and a shorter time to walking compared to alternative closure means. Use of the MANTA device in this study is experimental. All other parts of the procedure involve standard medical care
Health behaviors like physical activity and nutritious eating habits significantly reduce initial stroke risk and help prevent strokes from reoccurring. Yet, most individuals struggle to meet physical activity and nutrition recommendations. Health and health behaviors are typically linked in couples, and spouses occupy a unique position to facilitate each other’s physical activity and healthy nutrition, thereby reducing stroke risk for everyone involved.
The AMPLATZER LAA Occluder is a transcatheter, self-expanding nitinol device intended for use in preventing thrombus embolization from the LAA. The purpose of this study is to compile real world outcome data on the use of AMPLATZER LAA Occluder in subjects with non-valvular atrial fibrillation (NVAF)
We hope to understand a heart failure patient's journey during the transition of care from the emergency department or hospital to home. We also want to explore how technology, like home health monitoring, can better support patients' recovery during this time.
The purpose of this study is to determine if coronary artery disease (CAD) screening is necessary for patients on the waiting list for kidney transplantation. Patients on the waiting list for kidney transplantation are at risk for CAD. Currently, patients without any symptoms of CAD undergo annual testing to determine if they have disease. The optimal strategy to monitor and maintain the cardiac fitness of these patients is unknown.
Atrial fibrillation (AF) and atrial flutter (AFL) are cardiac rhythm problems where there is an irregular, rapid heart rate. Investigators plan to study Emergency Department (ED) patients with recent-onset episodes of AF or AFL (RAFF) where rapid heart rate requires urgent treatment to restore normal heart rhythm. RAFF is the most common rhythm disorder managed in the ED. Investigators recently showed that doctors use a wide variety of treatment approaches in Canadian EDs for RAFF.
This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours. Anyone diagnosed with a minor stroke faces the possibility of long-term disability and even death, regardless of treatment. Stroke symptoms such as weakness, difficulty speaking and paralysis may improve or worsen over the hours or days immediately following a stroke. TEMPO-2 is a minor stroke trial for patients presenting within 12 hours of their symptom onset. Patients will be randomized to TNK-tPA or standard of care.
The objective of C2R is to promote the rapid initiation and completion of enrollment in the CREST-2 randomized clinical trial (clinicaltrials.gov ID NCT02089217). Patients with severe symptomatic and asymptomatic carotid artery occlusive disease will be treated with carotid artery stenting (CAS) performed by experienced and skilled interventionists. Interventionists' eligibility will be determined by a multi-specialty Interventional Management Committee (IMC). Patient eligibility will include patients with standard or high-risk, symptomatic or asymptomatic carotid artery disease.
This is a prospective, multicenter, randomized, double-blinded clinical trial exploring the efficacy and safety of rivaroxaban as compared to acetylsalicylic acid in reducing stroke, transient ischemic attack (TIA) and neurocognitive decline, in subjects with non-valvular AF and with low risk of stroke.
This study will assess whether an implantable defibrillator will increase the likelihood of survival in patients who have had a heart attack in the prior year, have abnormal test results from a 24 hour heart monitor, and who have low normal heart function.
Rationale: To date, anticoagulant therapy in acute stroke has also been limited by excess hemorrhagic events. The oral anticoagulant dabigatran is a novel agent, which has been shown to be associated with much lower intracranial hemorrhage rates. It has been suggested that this agent may provide the superior benefits of anticoagulation in acute stroke, without the concomitant increase in hemorrhage risk associated with heparin/LMWH or warfarin.